參考文獻 |
1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018. 68(6): p. 394-424.
2. Chen, Y.-P., et al., Nasopharyngeal carcinoma. 2019. 394(10192): p. 64-80.
3. Mimi, C.Y. and J.-M. Yuan. Epidemiology of nasopharyngeal carcinoma. in Seminars in cancer biology. 2002. Elsevier.
4. Chang, E.T., H.-O.J.C.E. Adami, and P. Biomarkers, The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiology and Prevention Biomarkers, 2006. 15(10): p. 1765-1777.
5. Lo, K.W., K.F. To, and D.P.J.C.c. Huang, Focus on nasopharyngeal carcinoma. Cancer cell, 2004. 5(5): p. 423-428.
6. Tsao, S.W., et al., The role of Epstein–Barr virus in epithelial malignancies. The Journal of pathology, 2015. 235(2): p. 323-333.
7. Chan, S., et al., HLA and nasopharyngeal carcinoma in Chinese—a further study. 1983. 32(2): p. 171-176.
8. Lu, C.C., et al., Genetic susceptibility to nasopharyngeal carcinoma within the HLA‐A locus in Taiwanese. International journal of cancer, 2003. 103(6): p. 745-751.
9. Kongruttanachok, N., et al., Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. BMC cancer, 2001. 1(1): p. 1-5.
10. Nebert, D.W.J.M.R.F. and M.M.o. Mutagenesis, Role of genetics and drug metabolism in human cancer risk. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 1991. 247(2): p. 267-281.
11. Li, Y.Y., et al., Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature communications, 2017. 8(1): p. 1-10.
12. Teo, P.M., et al., Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society, 1996. 77(12): p. 2423-2431.
13. Yeh, S.-A., et al., Treatment outcomes of patients with AJCC stage IVC nasopharyngeal carcinoma: benefits of primary radiotherapy. Japanese journal of clinical oncology, 2006. 36(3): p. 132-136.
14. Hall, A.J.C. and M. Reviews, The cytoskeleton and cancer. Cancer and Metastasis Reviews, 2009. 28(1): p. 5-14.
15. Lee, A., et al., Management of nasopharyngeal carcinoma: current practice and future perspective. 2015. 33(29): p. 3356-3364.
16. Dorsam, R.T. and J.S.J.N.r.c. Gutkind, G-protein-coupled receptors and cancer. 2007. 7(2): p. 79-94.
17. Wootten, D., et al., Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nature reviews Molecular cell biology, 2018. 19(10): p. 638-653.
18. He, J.C., et al., The Gαo/i-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. Journal of Biological Chemistry, 2005. 280(39): p. 33426-33434.
19. Liu, S.-C., et al., Gα12-mediated pathway promotes invasiveness of nasopharyngeal carcinoma by modulating actin cytoskeleton reorganization. 2009. 69(15): p. 6122-6130.
20. Sah, V.P., et al., The role of Rho in G protein-coupled receptor signal transduction. Annual review of pharmacology and toxicology, 2000. 40: p. 459.
21. Kelly, P., et al., A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. Journal of Biological Chemistry, 2006. 281(36): p. 26483-26490.
22. Zhang, C., et al., High-resolution crystal structure of human protease-activated receptor 1. Nature, 2012. 492(7429): p. 387-392.
23. Coughlin, S.R.J.N., Thrombin signalling and protease-activated receptors. Nature 2000. 407(6801): p. 258-264.
24. Leger, A.J., L. Covic, and A.J.C. Kuliopulos, Protease-activated receptors in cardiovascular diseases. Circulation, 2006. 114(10): p. 1070-1077.
25. Liu, X., et al., Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer. Oncotarget, 2017. 8(63): p. 107334.
26. Macfarlane, S.R., et al., Proteinase-activated receptors. Pharmacological reviews, 2001. 53(2): p. 245-282.
27. Mo, J.-S., et al., Regulation of the Hippo–YAP pathway by protease-activated receptors (PARs). Genes & development, 2012. 26(19): p. 2138-2143.
28. Saleiban, A., et al., miR‐20b regulates expression of proteinase‐activated receptor‐1 (PAR‐1) thrombin receptor in melanoma cells. Pigment cell & melanoma research, 2014. 27(3): p. 431-441.
29. Wang, Q., et al., Endothelial cell protein C receptor promotes MGC803 gastric cancer cells proliferation and migration by activating ERK1/2. Medical Oncology, 2015. 32(5): p. 1-8.
30. Morris, D.R., et al., Protease-activated receptor-2 is essential for factor viia and xa–induced signaling, migration, and invasion of breast cancer cells. Cancer research, 2006. 66(1): p. 307-314.
31. Zhu, Q., et al., The activation of protease-activated receptor 1 mediates proliferation and invasion of nasopharyngeal carcinoma cells. Oncology reports, 2012. 28(1): p. 255-261.
32. Auvergne, R., et al., PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo. Oncogene, 2016. 35(29): p. 3817-3828.
33. Baker, N.C., et al., Overview of the 2014 food and drug administration cardiovascular and renal drugs advisory committee meeting about vorapaxar. Circulation, 2014. 130(15): p. 1287-1294.
34. Auernhammer, C. and S.J.E.r. Melmed, Leukemia-inhibitory factor—neuroimmune modulator of endocrine function. 2000. 21(3): p. 313-345.
35. Taga, T. and T.J.A.r.o.i. Kishimoto, Gp130 and the interleukin-6 family of cytokines. 1997. 15(1): p. 797-819.
36. Gearing, D.P.J.A.i.i., The leukemia inhibitory factor and its receptor. 1993. 53: p. 31-58.
37. Burdon, T., A. Smith, and P.J.T.i.c.b. Savatier, Signalling, cell cycle and pluripotency in embryonic stem cells. 2002. 12(9): p. 432-438.
38. Nicola, N.A., J.J.J.C. Babon, and g.f. reviews, Leukemia inhibitory factor (LIF). 2015. 26(5): p. 533-544.
39. Liu, S.-C., et al., Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. 2013. 123(12): p. 5269-5283.
40. Zhang, Y.S., et al., STAT 4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation. 2019. 38(6): p. 1-20.
41. Morris, M.A., C.W. Dawson, and L.S.J.F.o. Young, Role of the Epstein–Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future oncology, 2009. 5(6): p. 811-825.
42. Zheng, H., et al., Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol, 2007. 4(3): p. 185-196.
43. Liu, S.-C., et al., Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling. Nature communications, 2018. 9(1): p. 1-16.
44. Hong, W. and K.-L. Guan. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. in Seminars in cell & developmental biology. 2012. Elsevier.
45. Kango‐Singh, M. and A.J.D.d.a.o.p.o.t.A.A.o.A. Singh, Regulation of organ size: insights from the Drosophila Hippo signaling pathway. an official publication of the American Association of Anatomists, 2009. 238(7): p. 1627-1637.
46. Lee, M.-J., et al., YAP and TAZ regulate skin wound healing. Journal of Investigative Dermatology, 2014. 134(2): p. 518-525.
47. Lian, I., et al., The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes & development, 2010. 24(11): p. 1106-1118.
48. Zanconato, F., M. Cordenonsi, and S.J.C.c. Piccolo, YAP/TAZ at the roots of cancer. Cancer cell, 2016. 29(6): p. 783-803.
49. Shreberk‐Shaked, M. and M.J.M.o. Oren, New insights into YAP/TAZ nucleo‐cytoplasmic shuttling: new cancer therapeutic opportunities? Molecular oncology, 2019. 13(6): p. 1335-1341.
50. Moroishi, T., C.G. Hansen, and K.-L.J.N.R.C. Guan, The emerging roles of YAP and TAZ in cancer. Nature Reviews Cancer, 2015. 15(2): p. 73-79.
51. Steinhardt, A.A., et al., Expression of Yes-associated protein in common solid tumors. Human pathology, 2008. 39(11): p. 1582-1589.
52. Overholtzer, M., et al., Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proceedings of the National Academy of Sciences, 2006. 103(33): p. 12405-12410.
53. Chen, D., et al., LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nature medicine, 2012. 18(10): p. 1511-1517.
54. Zucchini, C., et al., ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity. Journal of Experimental & Clinical Cancer Research, 2019. 38(1): p. 1-14.
55. Wei, H., et al., Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP‐TEAD complex. Cancer science, 2017. 108(3): p. 478-487.
56. Moya, I.M., et al., Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science, 2019. 366(6468): p. 1029-1034.
57. Chan, S.W., et al., A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. 2008. 68(8): p. 2592-2598.
58. Gupta, G.P. and J.J.C. Massagué, Cancer metastasis: building a framework. Cell, 2006. 127(4): p. 679-695.
59. O’Hayre, M., M.S. Degese, and J.S.J.C.o.i.c.b. Gutkind, Novel insights into G protein and G protein-coupled receptor signaling in cancer. Current opinion in cell biology, 2014. 27: p. 126-135. |